FDA Prohibition of Saw Palmetto/BPH Treatment Claim Upheld by Court
This article was originally published in The Tan Sheet
Executive Summary
FDA's decision to deny a health claim linking saw palmetto extract to the treatment of benign prostatic hypertrophy symptoms was upheld by a Washington, D.C. federal court in a Jan. 3 decision